Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
RUNX3 encodes a member of the runt domain-containing family of transcription factors. Additionally we are shipping RUNX3 Proteins (12) and RUNX3 Kits (2) and many more products for this protein.
Showing 10 out of 181 products:
Human Polyclonal RUNX3 Primary Antibody for EIA, WB - ABIN954644
Tsang, Lamb, Romero-Gallo, Huang, Ito, Peek, Ito, Chen: Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. in Oncogene 2010
Show all 5 references for ABIN954644
Human Polyclonal RUNX3 Primary Antibody for ELISA, WB - ABIN560191
Nakamura, Senzaki, Yoshikawa, Nishimura, Inoue, Ito, Ozaki, Shiga: Dynamic regulation of the expression of neurotrophin receptors by Runx3. in Development (Cambridge, England) 2008
Show all 5 references for ABIN560191
Human Monoclonal RUNX3 Primary Antibody for FACS, ICC - ABIN4899364
Chopin, Seillet, Chevrier, Wu, Wang, Morse, Belz, Nutt: Langerhans cells are generated by two distinct PU.1-dependent transcriptional networks. in The Journal of experimental medicine 2013
Show all 2 references for ABIN4899364
Human Monoclonal RUNX3 Primary Antibody for ICC, FACS - ABIN1724742
Mei, Bai, Liu, Li, Wu, Yu, Zheng: RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. in Journal of cancer research and clinical oncology 2011
Human Polyclonal RUNX3 Primary Antibody for IF, IHC (p) - ABIN658684
Zhu, Xu, Hu, Feng, Jiang, Hou, Cao, Han, Ling, Ge: Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. in Journal of experimental & clinical cancer research : CR 2015
Cow (Bovine) Polyclonal RUNX3 Primary Antibody for WB - ABIN2780022
Yarmus, Woolf, Bernstein, Fainaru, Negreanu, Levanon, Groner: Groucho/transducin-like Enhancer-of-split (TLE)-dependent and -independent transcriptional regulation by Runx3. in Proceedings of the National Academy of Sciences of the United States of America 2006
successive induction of the transcription factors Runx3, Egr1 and Sox9b constitutes a regulatory cascade that controls expression of Follistatin A in pharyngeal endoderm, the latter modulating BMP signaling in developing cranial cartilage in zebrafish
Runx3 expression leads to an increase in primitive blood cell numbers, together with an increase in runx1 (show RUNX1 Antibodies)-expressing cells in the ventral wall of the dorsal aorta.
Zebrafish embryos lacking Rad21 (show RAD21 Antibodies), or cohesin subunit Smc3 (show SMC3 Antibodies), fail to express runx3 and lose hematopoietic runx1 (show RUNX1 Antibodies) expression in early embryonic development.
our data suggest that Runx3 may play a crucial role in the development of DRGs by regulating the expression of Ntrk3 (show NTRK3 Antibodies) variants
Runx3 is crucial for the phenotypic and functional changes observed in ThPok (show ZBTB7B Antibodies)-deficient invariant natural killer T cells.
the transcription factor Runx3 was essential for the normal development of subsets of innate lymphoid cells (ILCs) in the mucosa
Runx1 and Runx3 are the downstream effectors of Nanog, especially in the early and intermediate osteogenic differentiation of the mouse mesenchymal cell line C3H10T1/2.
nonpermissive expression of RUNX3 protein is restricted at the translational level, and that the repression is further enforced by a transcriptional regulation for maintenance of diverse developmental plasticity of T cells for different effector subsets.
Our findings establish Nr4a1 (show NR4A1 Antibodies) as a novel and critical player in the regulation of CD8 (show CD8A Antibodies) T cell development through the direct suppression of Runx3.
Runx1 (show RUNX1 Antibodies) Runx3 DKO mice exhibit bone marrow failure and myeloproliferative disorder. RUNX proteins are important for FANCD2 (show FANCD2 Antibodies) recruitment to DNA repair foci.
inflammation-mediated tumor promotion requires leukocytic Runx3 expression
Bone histomorphometry revealed that decreased osteoblast numbers and reduced mineral deposition capacity in Runx3-deficient mice cause this bone formation deficiency.
RUNX3 expression suppresses metastasis and angiogenesis of human prostate cancer.
miR (show MLXIP Antibodies)-148a-3p may regulate RUNX3 expression through the modulation of DNMT1 (show DNMT1 Antibodies)-dependent DNA methylation (show HELLS Antibodies) in laryngeal squamous cell carcinoma.
miR (show MLXIP Antibodies)-130b expression was downregulated, while RUNX3 mRNA was upregulated, in EOC tissues compared to normal ovarian tissues (both P=0.001). Importantly, the expression level of miR (show MLXIP Antibodies)-130b in EOC tissues was negatively correlated with that of RUNX3 mRNA significantly.
N-myc protein (show MYCN Antibodies) also could bind to the promoter of pri-miR (show MLXIP Antibodies)-4295 and inhibit the expression of RUNX3 in glioma cells.
miR (show MLXIP Antibodies)-532-5p functions as an oncogenic miRNA by promoting cell growth, migration and invasion in human gastric cancer cells via regulation of RUNX3 gene expression.
loss of RUNX3 expression contributed to 5-FU and CDDP resistance by inducing multidrug resistance proteins expression.
Results show up-regulation of TrkB (show NTRK2 Antibodies) and down-regulation of Runx3 and Keap1 (show KEAP1 Antibodies) in breast cancer cells and suggest that TrkB (show NTRK2 Antibodies) plays a key role in tumorigenicity and metastasis of breast cancer cells through suppression of Runx3 or Keap1 (show KEAP1 Antibodies).
In the present review, we summarize the proposed roles of RUNX3 in metastasis and, when applicable, highlight the mechanism by which they function.
the AA genotype and A allele of rs2236852 polymorphism confer a decreased CRC (show CALR Antibodies) risk, while the TA haplotype (rs760805 and rs2236852) increases the risk for CRC (show CALR Antibodies) development in Mexican patients.
HMGB1 (show HMGB1 Antibodies) contributed to IFN-gamma (show IFNG Antibodies)-producing Th17-cell bias in coronary artery atherosclerosis by controlling expression of T-bet and RUNX3.
Targeting miR (show MLXIP Antibodies)-130a and miR (show MLXIP Antibodies)-495 could be a potential therapeutics to recover RUNX3 expression under hypoxic conditions and in early tumorigenic progression.
This gene encodes a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
runt-related transcription factor b
, runt-related transcription factor 3
, core-binding factor 3
, PEA2-alpha C
, PEBP2-alpha C
, SL3-3 enhancer factor 1 alpha C subunit
, SL3/AKV core-binding factor alpha C subunit
, acute myeloid leukemia 2 protein
, core binding factor alpha 3
, core-binding factor subunit alpha-3
, oncogene AML-2
, polyomavirus enhancer-binding protein 2 alpha C subunit
, runt domain, alpha subunit 3
, transcription factor AML2/CBFA3
, PEA2 alpha C
, PEBP2 alpha C
, acute myeloid leukemia gene 2
, core-binding factor, runt domain, alpha subunit 3
, transcription factor AML2
, Runt related transcription factor 3
, Runx3 MASN-variant